Cosmetic outcome and incidence of infection with the MammoSite breast brachytherapy applicator

被引:23
作者
Dickler, A
Kirk, MC
Choo, J
Hsi, WC
Chu, J
Dowlatshahi, K
Francescatti, D
Shott, S
Nguyen, C
机构
[1] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Gen Surg, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Dept Med, Biostat Unit, Chicago, IL 60612 USA
关键词
brachytherapy; breast cancer; MammoSite; radiation;
D O I
10.1111/j.1075-122X.2005.00014.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
We present our results regarding the cosmetic outcome achieved and the rate of infection using the MammoSite breast brachytherapy applicator to treat patients with partial breast irradiation. In addition, factors associated with cosmetic outcome and infection are analyzed. The study population consisted of 30 patients with early stage breast cancer treated using the MammoSite device from October 28, 2002, to February 13, 2004. Cosmetic outcome was analyzed for its association with the following parameters: volume of the balloon, balloon-to-skin distance, maximal skin point dose per fraction, V-100 (percent of volume that received 100% of the prescription dose), V-150 (percent of volume that received 150% of the prescription dose), and V-200 (percent of volume that received 200% of the prescription dose). The occurrence of infection at the time of treatment and during follow-up was also recorded. At a median follow-up of 13 months (range 1-16 months), 53.3% of the patients (16/30) were reported to have an excellent cosmetic outcome and 40.0% (12/30) had a good cosmetic outcome. Excellent cosmetic outcome was associated with a greater mean balloon-to-skin distance compared to those who achieved a good cosmetic outcome (1.5 cm versus 1.2 cm) (p = 0.164). The mean V-100, V-150, and V-200 of those in the excellent cosmetic outcome group were 92.1%,34.5%, and 7.6% versus 93.0%, 34.7%, and 7.6% in the good cosmetic outcome group (p = 0.642, 0.926, and 0.853), The mean balloon volumes were 47.7 cm(3) and 56.9 cm(3), respectively (p = 0.063) in the excellent and good outcome groups. The mean maximal skin doses perfraction in the excellent and good outcome groups were 354.8 cGy and 422.3 cGy (p = 0.286), respectively. Infection occurred in 13.3% of the patients (4/30). An excellent or good cosmetic outcome was achieved in 93.3% of patients and infection occurred in 13.3% of patients treated with the MammoSite breast brachytherapy applicator. Excellent cosmetic outcome was associated with a greater balloon-to-skin distance, lower maximal skin dose per fraction, and smaller mean balloon volume; however, the results did not reach statistical significance.
引用
收藏
页码:306 / 310
页数:5
相关论文
共 20 条
[1]
The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy [J].
Baglan, KL ;
Martinez, AA ;
Frazier, RC ;
Kini, VR ;
Kestin, LL ;
Chen, PY ;
Edmundson, G ;
Mele, E ;
Jaffray, D ;
Vicini, FA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (04) :1003-1011
[2]
DICKLER A, 2004, INT J RADIAT ONCOL, V59, P456
[3]
Low use of breast conservation surgery in medically indigent populations [J].
Dolan, JT ;
Granchi, TS ;
Miller, CC ;
Brunicardi, FC .
AMERICAN JOURNAL OF SURGERY, 1999, 178 (06) :470-473
[4]
Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator [J].
Edmundson, GK ;
Vicini, FA ;
Chen, PY ;
Mitchell, C ;
Martinez, AA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (04) :1132-1139
[5]
GEOGRAPHIC-VARIATION IN THE TREATMENT OF LOCALIZED BREAST-CANCER [J].
FARROW, DC ;
HUNT, WC ;
SAMET, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (17) :1097-1101
[6]
CONSERVATIVE SURGERY FOR THE MANAGEMENT OF INVASIVE AND NONINVASIVE CARCINOMA OF THE BREAST - NSABP TRIALS [J].
FISHER, B ;
ANDERSON, S .
WORLD JOURNAL OF SURGERY, 1994, 18 (01) :63-69
[7]
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer [J].
Fisher, B ;
Anderson, S ;
Bryant, J ;
Margolese, RG ;
Deutsch, M ;
Fisher, ER ;
Jeong, J ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (16) :1233-1241
[8]
ANALYSIS OF COSMETIC RESULTS FOLLOWING PRIMARY RADIATION-THERAPY FOR STAGE-1 AND STAGE-2 CARCINOMA OF THE BREAST [J].
HARRIS, JR ;
LEVENE, MB ;
SVENSSON, G ;
HELLMAN, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1979, 5 (02) :257-261
[9]
Thirty month results with the MammoSite breast brachytherapy applicator: Cosmesis, toxicity and local control in partial breast irradiation [J].
Keisch, M ;
Vicini, F ;
Scroggins, T ;
Hebert, M ;
White, J ;
Quiet, C ;
Kuske, R ;
Arthur, D ;
Streeter, O .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01) :S272-S272
[10]
Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy [J].
Keisch, M ;
Vicini, F ;
Kuske, RR ;
Hebert, M ;
White, J ;
Quiet, C ;
Arthur, D ;
Scroggins, T ;
Streeter, O .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (02) :289-293